ReviewFrontiers in pharmacology2025
An overview of insights and updates on TTN mutations in cardiomyopathies.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hypertrophic cardiomyopathy: comprehensive insights into pathogenic genes and genotype-phenotype associations.Frontiers in cell and developmental biology · 2026Review
- Spectrum and Clinical Interpretation ofInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the heart muscle, the largest sarcomeric protein is titin (TTN). The heart expresses two principal isoforms, N2B and N2BA, which arise from alternative splicing of the TTN gene. These isoforms span four distinct regions of the sarcomere: the Z-line, I-band, A-band, and M-line. Titin, encoded by the extensive TTN gene consisting of 364 exons, plays a critical role in the structural integrity, development, mechanical properties, and regulation of both cardiac and skeletal muscles. The purpose of this review is to provide a comprehensive understanding of the critical role TTN mutations play in DCM and other forms of cardiomyopathy. With the advent of next-generation sequencing (NGS), it has become feasible to simultaneously analyse numerous genes, including large and complex ones such as TTN. TTN truncations are frequently observed in dilated cardiomyopathy (DCM), whereas they are comparatively rare in hypertrophic cardiomyopathy (HCM). Furthermore, TTN mutations have been implicated in arrhythmogenic right ventricular cardiomyopathy (ARVC), a distinct clinical entity with characteristic features and outcomes. The discovery of a rare TTN missense variant that co-segregates with restrictive cardiomyopathy (RCM) strongly suggests that TTN may represent a novel causative gene in this severe cardiomyopathy. Furthermore, we highlight the significant implications of these findings for advancing both basic research and clinical practice in cardiovascular medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.